Neumora Therapeutics, Inc. (NMRA) total liabilities
Neumora Therapeutics, Inc. (NMRA) had total liabilities of $87.18M at the end of fiscal 2025 (December 31, 2025). That is 191.5% higher than the $29.91M of fiscal 2024. Figures as of 19 Nov 2026, 13:21 UTC, from Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $87.18M
- Change on fiscal 2024
- +191.5%
- Highest on record
- $873.08Mfiscal 2022
- Lowest on record
- $27.12Mfiscal 2023
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.
Neumora Therapeutics, Inc. total liabilities, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $873.08M in fiscal 2022 and the lowest $27.12M in fiscal 2023.
Total liabilities by fiscal year
Neumora Therapeutics, Inc. total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $87.18M | 191.5% up | |
| 2024 | $29.91M | 10.3% up | |
| 2023 | $27.12M | 96.9% down | |
| 2022 | $873.08M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Neumora Therapeutics, Inc., figure by figure
- Neumora Therapeutics, Inc. market cap
- Neumora Therapeutics, Inc. revenue
- Neumora Therapeutics, Inc. earnings
- Neumora Therapeutics, Inc. earnings per share (EPS)
- Neumora Therapeutics, Inc. P/E ratio
- Neumora Therapeutics, Inc. P/S ratio
- Neumora Therapeutics, Inc. P/B ratio
- Neumora Therapeutics, Inc. free cash flow
- Neumora Therapeutics, Inc. operating margin
- Neumora Therapeutics, Inc. dividend
- Neumora Therapeutics, Inc. shares outstanding
- Neumora Therapeutics, Inc. total debt
- Neumora Therapeutics, Inc. cash on hand
- Neumora Therapeutics, Inc. total assets
- Neumora Therapeutics, Inc. net assets (shareholders' equity)
- Neumora Therapeutics, Inc. return on equity (ROE)
- Neumora Therapeutics, Inc. return on invested capital (ROIC)
Neumora Therapeutics, Inc. (NMRA) overview: price, valuation and scorecard
Neumora Therapeutics, Inc. total liabilities: questions and answers
How large are Neumora Therapeutics, Inc.'s total liabilities?
Neumora Therapeutics, Inc. (NMRA) had total liabilities of $87.18M at the end of fiscal 2025 (December 31, 2025). That is 191.5% higher than the $29.91M of fiscal 2024.
What are the highest and lowest total liabilities figures on record for Neumora Therapeutics, Inc.?
Across the 4 fiscal years on record (2022–2025), the highest was $873.08M in fiscal 2022 and the lowest $27.12M in fiscal 2023.
How is Neumora Therapeutics, Inc.'s total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Neumora Therapeutics, Inc. it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Neumora Therapeutics, Inc. (NMRA) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/NMRA/total-liabilities
Underlying data: Yahoo Finance.